A Public Health Approach to the Prevention of Inhibitors in Hemophilia

Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Oakley, Meredith; Brown, Deborah L.; Kucab, Phillip

Back to Previous Page

- Add this to...
- Twitter
- Facebook
- Google Bookmarks
- LinkedIn

A Public Health Approach to the Prevention of Inhibitors in Hemophilia

Published Date:

Sep 19 2014

Source:

Am J Prev Med. 47(5):669-673.

[PDF-70.61 KB]

Details:

Personal Authors:

Soucie, J. Michael ; Miller, Connie H. ; Kelly, Fiona M. ; Oakley, Meredith ; Brown, Deborah L. ; ... More ▼

Keywords:

[+]

Pubmed ID:

25245801

Pubmed Central ID:

PMC4469363

Description:

The development of an antibody in people with hemophilia to products used in the treatment and prevention of bleeding, also referred to as an inhibitor, is the most serious complication of hemophilia care today. CDC, together with healthcare providers, consumer organizations, hemophilia organizations, and federal partners, has developed a public health agenda to prevent the development of inhibitors. This paper describes a public health approach that combines a national surveillance program with epidemiologic, laboratory, and prevention research to address knowledge gaps in rates and risk factors for inhibitor development, and in knowledge and behaviors of patients and providers, in addition to screening and treatment practices.

Document Type:

Journal Article

Collection(s):

CDC Public Access

Funding:

CC999999/Intramural CDC HHS/United States

Main Document Checksum:

[+]

Supporting Files:

nihms699357.nxml

text/xml

No Related Documents.

You May Also Like:

Improving the performance of factor VIII inhibitor tests in hemophilia A

Personal Author:

Miller, Connie H.

Published:

Sep 28 2015

Source:

Thromb Res. 136(6):1047-1048.

File Type:

[PDF - 41.93 KB]
Achievements, challenges and unmet needs for haemophilia patients with inhibitors

Personal Author:

DARGAUD, Y.; PAVLOVA, A.; LACROIX-DESMAZES, S.; FISCHER, K.; SOUCIE, M.; CLAEYSSENS, S.; SCOTT, D.W.; d’OIRON, R.; LAVIGNE-LISSALDE, G.; KENET, G.; ETTINGSHAUSEN, C. ESCURIOLA; BOREL-DERLON, A.; LAMBERT, T.; PASTA, G.; NÉGRIER, C.;

Published:

Jan 2016

Source:

Haemophilia. 22(Suppl 1):1-24.

Description:

Over the past 20 years, there have been many advances in haemophilia treatment that have allowed patients to take greater control of their disease. However, the development of factor VIII (FVIII) inhibitors is the greatest complication of the disease...

File Type:

[PDF - 638.38 KB]
National surveillance for hemophilia inhibitors in the United States: Summary report of an expert meeting

Personal Author:

Soucie, J. Michael; Miller, Connie H.; Kelly, Fiona M.; Aschman, Diane; DiMichele, Donna; Konkle, Barbara A.; Kulkarni, Roshni; Monahan, Paul E.;

Published:

Apr 10 2014

Source:

Am J Hematol. 2014; 89(6):621-625.

Description:

On March 12, 2012, the Centers for Disease Control and Prevention (CDC) held a meeting of its partners in hemophilia treatment, community-based organizations, industry, and government to review data and discuss implementation issues relevant to plann...

File Type:

[PDF - 122.10 KB]
Prevalent Inhibitors in Hemophilia B Subjects Enrolled in the Universal Data Collection Database

Personal Author:

Puetz, John; Soucie, J. Michael; Kempton, Christine L.; Monahan, Paul E.;

Corporate Author:

Hemophilia Treatment Center Network (HTCN) Investigators

Published:

Jul 16 2013

Source:

Haemophilia. 20(1):25-31

Description:

Background : Several risk factors for inhibitors have recently been described for hemophilia A. It has been assumed that similar risk factors are also relevant for hemophilia B, but there is limited data to confirm this notion. : Objectives : To dete...

File Type:

[PDF - 210.14 KB]
Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis

Personal Author:

Grosse, Scott D; Chaugule, Shraddha S; Hay, Joel W;

Published:

Jan 14 2015

Source:

Expert Rev Pharmacoecon Outcomes Res. 2015; 15(2):267-283

Description:

Estimates of preference-weighted health outcomes or health state utilities are needed to assess improvements in health in terms of quality-adjusted life-years. Gains in quality-adjusted life-years are used to assess the cost-effectiveness of prophyla...

File Type:

[PDF - 288.49 KB]